BT
Byongen Therapeutics
The company develops next-generation adeno-associated virus (AAV) gene delivery vectors through capsid modification. These modified AAV vectors provide precise and safe in vivo gene delivery for gene therapy applications.
Traction –/10
Beijing, China · HQ
- Biotechnology
Updated 5 months ago
Funding
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The company develops next-generation adeno-associated virus (AAV) gene delivery vectors through capsid modification. These modified AAV vectors provide precise and safe in vivo gene delivery for gene therapy applications.